MLRagent

Rules

Aboutfair balancerisk disclosureindication on labelsubstantiationcomparativemisleading presentationname ingredientsubmissionpre approvalscientific exchangedisclosure
TrustAI-verifiedDisputedDraft
Severityblockerwarningnote
Decided bya checkhuman judgment
Naturepromotional
Basisconsistent-with-labelingunsolicited-requestunapproved-use-scientific
Audiencehcpconsumer
Document typeadvertisement
Risk info placementdistinct-part
Communication typeadvertisement
Mediumprintbroadcastdigitalsocialin-person
Regulatory classprescription-drug
Material typeprescription-drug-advertisementadvertisement
Launch stagepost-approvalpre-approval
Productdrugbiologicprescription-drug
Drug classprescription
Rx statusprescription
Advertising typeprescription-drug-advertisement
Populationhuman-use
Content triggerliterature-or-study-effectiveness-claim
Materialadvertisement
Content typeadvertisement
Active ingredient counttwo-or-more
Proprietary name basismixture-designation
Established name statusnone-for-mixture-designation
Drug classificationprescription
Labeling scenariosingle-proprietary-name-multiple-preparations-no-established-name
Prescription statusprescription-drug
Ad exemptionexcludes-reminder-adsexcludes-bulk-sale-drug-adsexcludes-prescription-compounding-drug-ads
Ad formattelevision
Intended specieshuman
Exemption statusnon-exempt
Approval pathwayaccelerated

8 of 251 rules — including rules the source does not limit to any one scope

US-IND-005·21 CFR 202.1(e)(6)(xix)Disputed
Dosage safe for one patient class may not be implied safe/effective for another
blockerneeds human judgment
US-IND-012·Q.2/A.2, Factor 3Disputed
Communication is not consistent when labeling does not enable safe and effective use as suggested
blockerneeds human judgment
US-MIS-002·21 CFR 202.1(e)(3)(i)Disputed
Misleading omissions in prescription drug ads require added qualification within that part/theme
blockerneeds human judgment
US-MIS-013·21 CFR 202.1(e)(6)(xiv)Disputed
No misleading pooled statistics in prescription drug advertising
blockerneeds human judgment
US-NAME-007·21 CFR 202.1(b)(1)Disputed
Established name must accompany proprietary name each time featured in prescription drug ads
blockerneeds human judgment
US-NAME-008·21 CFR 202.1(b)(1)Disputed
Established name must appear with proprietary name in running text
blockerneeds human judgment
US-NAME-011·21 CFR 202.1(b)(2)Disputed
Established-name lettering ≥ half size of featured proprietary name in Rx drug ads
blockerneeds human judgment
US-RISK-001·21 CFR 202.1(e)(1)-(3)Disputed
Prescription drug ads need true brief summary, with broadcast alternative
blockerneeds human judgment